Clinical Trials Logo

Mycobacterium Infections clinical trials

View clinical trials related to Mycobacterium Infections.

Filter by:

NCT ID: NCT01051752 Completed - Clinical trials for Nontuberculous Mycobacterial Diseases

PK and PD of Drugs for Nontuberculous Mycobacterial Diseases in Dutch Patients

NTM
Start date: January 2010
Phase: N/A
Study type: Observational

A prospective observational study in which pharmacokinetic and pharmacodynamic parameters are evaluated in a cohort of patients with NTM diseases.

NCT ID: NCT00999076 Terminated - Clinical trials for Mycobacterium Infections

Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory Specimens

Start date: September 2009
Phase: N/A
Study type: Observational

The aim of the study is to evaluate the polymerase chain reaction (PCR)-Reverse Blot Hybridization Assay (REBA) for identification of nontuberculous mycobacteria (NTM) species in acid-fast bacilli (AFB) smear-positive respiratory specimens.

NCT ID: NCT00826423 Completed - Clinical trials for Mycobacterium Avium Intracellulare Complex (MAC)

Mycobacterium Avium Intracellulare Complex (MAC) Study

MAC
Start date: June 2008
Phase: N/A
Study type: Observational

This study is short course (3 month) multiple drug antibiotic therapy. The purpose of this research study is to evaluate the clinical and radiology response to assess whether drug resistance develops and assess quality of life measures with MAC disease.

NCT ID: NCT00814827 Active, not recruiting - Clinical trials for Opportunistic Infections

Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma

Start date: January 7, 2010
Phase:
Study type: Observational

Opportunistic infections are caused by bacteria, mycobacteria, fungi or viruses that do not normally cause infections in people with healthy immune systems. Some of these infections can cause public health concerns, especially in areas with limited access to treatment. People who acquire opportunistic infections usually have diseases that affect their immune systems, such as human immunodeficiency virus (HIV), or do not have enough white blood cells to fight the infection. However, some people acquire opportunistic infections even though they have normal amounts of white blood cells and are free from known diseases that harm their immune systems. This study will investigate some of the reasons that otherwise healthy people get opportunistic infections to learn more about why some people are more likely to have them. This study will include up to 210 HIV-negative males and females older than 18 years of age who have opportunistic infections. The patients will be drawn from multiple sites in Thailand and Taiwan including Khon Kaen University Hospital, Siriraj Hospital, Ramathibodi Hospital, National Taiwan University Hospital, National Cheng-Kung University Hospital Patients will undergo an initial evaluation that will include a physical examination, medical history, and blood and urine testing. Additional tests will be conducted if the researchers consider that the tests are medically necessary to treat the opportunistic infection; the results of the tests will be reviewed and saved for study purposes. Depending on the severity of the infection, the initial evaluation may take more than 1 day to complete. After the evaluation, patients will be given standard and appropriate medicines to treat the infections. Patients will return for follow-up visits to allow researchers to monitor their condition and to assess how well the patient is responding to the treatment. Patients will be evaluated by the study researchers at least once a year for 2 years following the initial treatment.

NCT ID: NCT00810446 Completed - Tuberculosis Clinical Trials

Safety And Efficacy Of Rifabutin In HIV Patients

Start date: June 2009
Phase:
Study type: Observational

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

NCT ID: NCT00810407 Completed - Tuberculosis Clinical Trials

Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients

Start date: November 2008
Phase:
Study type: Observational

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

NCT ID: NCT00751374 Not yet recruiting - Clinical trials for Rate of Exit Site Infection

Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis

Start date: September 2008
Phase: Phase 4
Study type: Interventional

Catheter-related infection, namely exit site infection and peritonitis, is the commonest complication of peritoneal dialysis. This complication causes significant morbidity and mortality in patients requiring peritoneal dialysis. Topical application of mupirocin 2% cream was first proven to be effective in reduction of staphylococcus-related catheter infection in 1990s. Subsequent randomized trial published in 2005 showed that gentamicin cream was superior to mupirocin 2% cream in reducing both Gram's positive and Gram's negative related catheter infection. However, a retrospective report published in 2007 puts the use of prophylactic antibiotic cream into a question. It reported an emergency of non-tuberculous mycobacterial infection in a dialysis center in Hong Kong after practising prophylactic application of gentamicin cream at the catheter exit site. The following prospective, randomized and open-label study aims to find out an optimal regimen of topical antibiotic prophylaxis in patients requiring peritoneal dialysis.

NCT ID: NCT00652067 Completed - Clinical trials for Infection, Mycobacterium Avium-Intracellulare

Clofazamine for the Treatment of Mycobacterium Avium Intracellulare(MAI)

Start date: May 2006
Phase: N/A
Study type: Observational

This protocol is an single patient IND to provide clofazamine to treat one patient who has MAI and is resistant to or can not tolerate standard of care. The drug is not otherwise available.

NCT ID: NCT00600769 Completed - Clinical trials for Mycobacterium Avium Complex

Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)

Start date: January 1991
Phase: Phase 4
Study type: Interventional

Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria

NCT ID: NCT00600600 Completed - Clinical trials for Rapidly Growing Mycobacterial Lung Disease

Tigecycline for Treatment of Rapidly Growing Mycobacteria

Start date: April 2002
Phase: Phase 2
Study type: Interventional

To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).